FOCUSED ON THE DEVELOPMENT OF TRANSFORMATIVE THERAPIES FOR THE TREATMENT OF WORSENING AND ACUTE DECOMPENSATED HEART FAILURE
Founded in 2021, Corteria Pharmaceuticals is a privately held company developing first-in-class drugs for indications of high unmet medical need, such as heart failure, sarcopenia and obesity subpopulations. Our strategy implies innovative patient stratification and target selection based on human evidence and a better understanding of the disease biology in patients.
We are using cutting-edge methods to stratify the patients and identify those who will benefit the most from our treatments. Our focus is on worsening and acute heart failure, right heart failure, sarcopenia (including age-related sarcopenia and obesity-related sarcopenia) and obesity with established complications.
We address a large spectrum of heart failure decompensation
With more than 60 million patients worldwide, heart failure is the only category of cardiovascular disease that continues to grow due to the aging population, increased incidence of diabetes, and persistent non-fatal myocardial infarction. Pulmonary congestion is recognized as the main symptom triggering unscheduled inpatient hospitalizations or outpatient visits to diuresis clinics.
Congestion is not always associated with low cardiac output, rather it is related to the stimulation of neuro-endocrine hormones that leads to excessive renal sodium and water reabsorption. Elevated fluid retention is aggravated in patients with pre-existing chronic kidney disease. Excess body fluid retention not only instigates pulmonary congestion and breathing difficulty, it also causes pulmonary hypertension and impairs the function of the skin, liver, kidney and intestine. A rapid onset of congestion results in acute decompensated heart failure, whereas a gradual development of congestion is associated with the worsening of signs and symptoms of heart failure and currently both conditions have high unmet medical needs.
VASOPRESSIN NEUTRALIZING ANTIBODY PROJECT